1190 related articles for article (PubMed ID: 29532550)
1. Fibroblast-matrix interplay: Nintedanib and pirfenidone modulate the effect of IPF fibroblast-conditioned matrix on normal fibroblast phenotype.
Epstein Shochet G; Wollin L; Shitrit D
Respirology; 2018 Aug; 23(8):756-763. PubMed ID: 29532550
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the antifibrotic effects of the pan-histone deacetylase-inhibitor panobinostat versus the IPF-drug pirfenidone in fibroblasts from patients with idiopathic pulmonary fibrosis.
Korfei M; Stelmaszek D; MacKenzie B; Skwarna S; Chillappagari S; Bach AC; Ruppert C; Saito S; Mahavadi P; Klepetko W; Fink L; Seeger W; Lasky JA; Pullamsetti SS; Krämer OH; Guenther A
PLoS One; 2018; 13(11):e0207915. PubMed ID: 30481203
[TBL] [Abstract][Full Text] [Related]
3. Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis.
Hostettler KE; Zhong J; Papakonstantinou E; Karakiulakis G; Tamm M; Seidel P; Sun Q; Mandal J; Lardinois D; Lambers C; Roth M
Respir Res; 2014 Dec; 15(1):157. PubMed ID: 25496490
[TBL] [Abstract][Full Text] [Related]
4. Suppression of TGF-β pathway by pirfenidone decreases extracellular matrix deposition in ocular fibroblasts in vitro.
Stahnke T; Kowtharapu BS; Stachs O; Schmitz KP; Wurm J; Wree A; Guthoff RF; Hovakimyan M
PLoS One; 2017; 12(2):e0172592. PubMed ID: 28231275
[TBL] [Abstract][Full Text] [Related]
5. Hypoxia Inducible Factor 1A Supports a Pro-Fibrotic Phenotype Loop in Idiopathic Pulmonary Fibrosis.
Epstein Shochet G; Bardenstein-Wald B; McElroy M; Kukuy A; Surber M; Edelstein E; Pertzov B; Kramer MR; Shitrit D
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33805152
[TBL] [Abstract][Full Text] [Related]
6. A Novel Antifibrotic Mechanism of Nintedanib and Pirfenidone. Inhibition of Collagen Fibril Assembly.
Knüppel L; Ishikawa Y; Aichler M; Heinzelmann K; Hatz R; Behr J; Walch A; Bächinger HP; Eickelberg O; Staab-Weijnitz CA
Am J Respir Cell Mol Biol; 2017 Jul; 57(1):77-90. PubMed ID: 28257580
[TBL] [Abstract][Full Text] [Related]
7. Effect of pirfenidone on proliferation, TGF-β-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts.
Conte E; Gili E; Fagone E; Fruciano M; Iemmolo M; Vancheri C
Eur J Pharm Sci; 2014 Jul; 58():13-9. PubMed ID: 24613900
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of mast cells: a novel mechanism by which nintedanib may elicit anti-fibrotic effects.
Overed-Sayer C; Miranda E; Dunmore R; Liarte Marin E; Beloki L; Rassl D; Parfrey H; Carruthers A; Chahboub A; Koch S; Güler-Gane G; Kuziora M; Lewis A; Murray L; May R; Clarke D
Thorax; 2020 Sep; 75(9):754-763. PubMed ID: 32709610
[TBL] [Abstract][Full Text] [Related]
9. Histopathological and molecular analysis of idiopathic pulmonary fibrosis lungs from patients treated with pirfenidone or nintedanib.
Zhang Y; Jones KD; Achtar-Zadeh N; Green G; Kukreja J; Xu B; Wolters PJ
Histopathology; 2019 Jan; 74(2):341-349. PubMed ID: 30152895
[TBL] [Abstract][Full Text] [Related]
10. Vardenafil Activity in Lung Fibrosis and In Vitro Synergy with Nintedanib.
Bourne MH; Kottom TJ; Hebrink DM; Choudhury M; Leof EB; Limper AH
Cells; 2021 Dec; 10(12):. PubMed ID: 34944010
[TBL] [Abstract][Full Text] [Related]
11. A Rnd3/p190RhoGAP pathway regulates RhoA activity in idiopathic pulmonary fibrosis fibroblasts.
Monaghan-Benson E; Wittchen ES; Doerschuk CM; Burridge K
Mol Biol Cell; 2018 Sep; 29(18):2165-2175. PubMed ID: 29995590
[TBL] [Abstract][Full Text] [Related]
12. Pirfenidone and nintedanib modulate properties of fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis.
Lehtonen ST; Veijola A; Karvonen H; Lappi-Blanco E; Sormunen R; Korpela S; Zagai U; Sköld MC; Kaarteenaho R
Respir Res; 2016 Feb; 17():14. PubMed ID: 26846335
[TBL] [Abstract][Full Text] [Related]
13. Regulation of Cellular Senescence Is Independent from Profibrotic Fibroblast-Deposited ECM.
Blokland KEC; Habibie H; Borghuis T; Teitsma GJ; Schuliga M; Melgert BN; Knight DA; Brandsma CA; Pouwels SD; Burgess JK
Cells; 2021 Jun; 10(7):. PubMed ID: 34209854
[TBL] [Abstract][Full Text] [Related]
14. Novel Mechanisms for the Antifibrotic Action of Nintedanib.
Rangarajan S; Kurundkar A; Kurundkar D; Bernard K; Sanders YY; Ding Q; Antony VB; Zhang J; Zmijewski J; Thannickal VJ
Am J Respir Cell Mol Biol; 2016 Jan; 54(1):51-9. PubMed ID: 26072676
[TBL] [Abstract][Full Text] [Related]
15. Anti-fibrotic effects of pirfenidone and rapamycin in primary IPF fibroblasts and human alveolar epithelial cells.
Molina-Molina M; Machahua-Huamani C; Vicens-Zygmunt V; Llatjós R; Escobar I; Sala-Llinas E; Luburich-Hernaiz P; Dorca J; Montes-Worboys A
BMC Pulm Med; 2018 Apr; 18(1):63. PubMed ID: 29703175
[TBL] [Abstract][Full Text] [Related]
16. Prolonged Scar-in-a-Jar: an in vitro screening tool for anti-fibrotic therapies using biomarkers of extracellular matrix synthesis.
Rønnow SR; Dabbagh RQ; Genovese F; Nanthakumar CB; Barrett VJ; Good RB; Brockbank S; Cruwys S; Jessen H; Sorensen GL; Karsdal MA; Leeming DJ; Sand JMB
Respir Res; 2020 May; 21(1):108. PubMed ID: 32381012
[TBL] [Abstract][Full Text] [Related]
17. Interferon-γ enhances the antifibrotic effects of pirfenidone by attenuating IPF lung fibroblast activation and differentiation.
Vu TN; Chen X; Foda HD; Smaldone GC; Hasaneen NA
Respir Res; 2019 Sep; 20(1):206. PubMed ID: 31511015
[TBL] [Abstract][Full Text] [Related]
18. Differential effects of Nintedanib and Pirfenidone on lung alveolar epithelial cell function in ex vivo murine and human lung tissue cultures of pulmonary fibrosis.
Lehmann M; Buhl L; Alsafadi HN; Klee S; Hermann S; Mutze K; Ota C; Lindner M; Behr J; Hilgendorff A; Wagner DE; Königshoff M
Respir Res; 2018 Sep; 19(1):175. PubMed ID: 30219058
[TBL] [Abstract][Full Text] [Related]
19. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis.
Wollin L; Wex E; Pautsch A; Schnapp G; Hostettler KE; Stowasser S; Kolb M
Eur Respir J; 2015 May; 45(5):1434-45. PubMed ID: 25745043
[TBL] [Abstract][Full Text] [Related]
20. Featured Article: TGF-β1 dominates extracellular matrix rigidity for inducing differentiation of human cardiac fibroblasts to myofibroblasts.
Cho N; Razipour SE; McCain ML
Exp Biol Med (Maywood); 2018 Apr; 243(7):601-612. PubMed ID: 29504479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
